User profiles for Justin T Jordan
 | Justin JordanAssociate Professor of Neurology, Harvard Medical School Verified email at mgh.harvard.edu Cited by 3303 |
Treatment for brain metastases: ASCO-SNO-ASTRO guideline
Purpose To provide guidance to clinicians regarding therapy for patients with brain
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …
Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma
…, JT Jordan, J de Groot, L Nghiemphu, T Kaley… - Clinical Cancer …, 2021 - AACR
Purpose: VEGF is upregulated in glioblastoma and may contribute to immunosuppression.
We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent …
We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent …
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy
JT Jordan, W Sun, SF Hussain, G DeAngulo… - Cancer Immunology …, 2008 - Springer
Despite the immunogenicity of glioblastoma multiforme (GBM), immune-mediated eradication
of these tumors remains deficient. Regulatory T cells (Tregs) in the blood and within the …
of these tumors remains deficient. Regulatory T cells (Tregs) in the blood and within the …
[HTML][HTML] Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation
…, D Halliday, CHHHA Heiberg, P Joly, JT Jordan… - Genetics in …, 2022 - Elsevier
Purpose Neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) are genetically distinct
tumor predisposition syndromes with overlapping phenotypes. We sought to update the …
tumor predisposition syndromes with overlapping phenotypes. We sought to update the …
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
P Karschnia, JT Jordan, DA Forst… - Blood, The Journal …, 2019 - ashpublications.org
Chimeric antigen receptor (CAR) T cells have emerged as a promising class of cell-based
immunotherapy in refractory malignancies. Neurotoxicity represents a common and potentially …
immunotherapy in refractory malignancies. Neurotoxicity represents a common and potentially …
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial
…, K Gallagher, M Roschewski, JT Jordan… - Blood, The Journal …, 2022 - ashpublications.org
CD19-directed chimerical antigen receptor T-cell (CAR-T) products have gained US Food
and Drug Administration approval for systemic large B-cell lymphoma. Because of concerns …
and Drug Administration approval for systemic large B-cell lymphoma. Because of concerns …
The use of MEK inhibitors in neurofibromatosis type 1–associated tumors and management of toxicities
LJ Klesse, JT Jordan, HB Radtke, T Rosser… - The …, 2020 - academic.oup.com
Neurofibromatosis type 1 (NF1) clinical care is on the cusp of a transformative shift. With the
success of recent clinical trials using MEK inhibitors, an increasing number of NF1 patients …
success of recent clinical trials using MEK inhibitors, an increasing number of NF1 patients …
Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline
…, LE Gaspar, V Gondi, JT Jordan… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE American Society of Radiation Oncology (ASTRO) has developed a guideline
on appropriate radiation therapy for brain metastases. ASCO has a policy and set of …
on appropriate radiation therapy for brain metastases. ASCO has a policy and set of …
Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies
Anti‐angiogenic therapy for glioblastoma has been in the spotlight for several years, as
researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. …
researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. …
[HTML][HTML] Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype …
Purpose Neurofibromatosis type 1 (NF1) is characterized by a highly variable clinical
presentation, but almost all NF1-affected adults present with cutaneous and/or subcutaneous …
presentation, but almost all NF1-affected adults present with cutaneous and/or subcutaneous …
